卡麦角林治疗高催乳素血症：直击问题核心 - Suppr

Suppr

超能文献

Cabergoline for hyperprolactinemia: getting to the heart of it.

作者信息

Nachtigall Lisa B

机构信息

Neuroendocrine Clinic Center, Massachusetts General Hospital, Zero Emerson Place Suite 112, Boston, MA, 02114, USA.

出版信息

Endocrine. 2017 Jul;57(1):3-5. doi: 10.1007/s12020-017-1271-z. Epub 2017 Mar 4.

DOI:10.1007/s12020-017-1271-z

PMID:28260205

Abstract

摘要

相似文献

Cabergoline for hyperprolactinemia: getting to the heart of it.卡麦角林治疗高催乳素血症：直击问题核心

Endocrine. 2017 Jul;57(1):3-5. doi: 10.1007/s12020-017-1271-z. Epub 2017 Mar 4.

AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.美国临床内分泌医师协会/美国内分泌学会疾病状态临床综述：多巴胺激动剂治疗高催乳素血症与心脏瓣膜病风险

Endocr Pract. 2014 Jun;20(6):608-16. doi: 10.4158/EP14148.RA.

Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.卡麦角林对泌乳素瘤和特发性高泌乳素血症患者瓣膜状态影响的前瞻性长期研究。

Endocrine. 2017 Jan;55(1):239-245. doi: 10.1007/s12020-016-1120-5. Epub 2016 Oct 5.

Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.卡麦角林，一种治疗催乳素瘤和非肿瘤性高催乳素血症的有前景的药物。

Intern Med. 2001 Sep;40(9):845-6. doi: 10.2169/internalmedicine.40.845.

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.卡麦角林治疗高催乳素血症：455例患者的研究

J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22. doi: 10.1210/jcem.84.7.5810.

Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.卡麦角林治疗利培酮所致高催乳素血症：一项初步研究。

J Clin Psychiatry. 2004 Feb;65(2):187-90. doi: 10.4088/jcp.v65n0207.

Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.多巴胺激动剂治疗儿童利培酮所致高催乳素血症

J Child Adolesc Psychopharmacol. 2001 Winter;11(4):435-40. doi: 10.1089/104454601317261618.

Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.阴道用卡麦角林治疗对口服多巴胺能药物不耐受的高泌乳素血症患者。

Fertil Steril. 1996 Feb;65(2):440-2. doi: 10.1016/s0015-0282(16)58113-8.

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.多巴胺激动剂溴隐亭和卡麦角林在治疗精神病性障碍患者利培酮所致高催乳素血症中的应用。

J Endocrinol Invest. 2000 Dec;23(11):765-70. doi: 10.1007/BF03345068.

Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.卡麦角林治疗的泌乳素瘤患者当前的药物撤药策略：一项系统评价和荟萃分析。

Pituitary. 2015 Oct;18(5):745-51. doi: 10.1007/s11102-014-0617-2.

引用本文的文献

Efficacy of Metformin-Cabergoline Compared to Metformin Monotherapy for Management of PCOS With Hyperprolactinemia: A Systematic Review and Meta-analysis.二甲双胍联合卡麦角林与二甲双胍单药治疗高催乳素血症性多囊卵巢综合征的疗效：一项系统评价和荟萃分析

Clin Med Insights Endocrinol Diabetes. 2024 Sep 16;17:11795514241280028. doi: 10.1177/11795514241280028. eCollection 2024.

FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years.美国食品药品监督管理局批准的含二甲胺药效基团的药物：过去50年回顾

RSC Adv. 2024 Sep 2;14(38):27657-27696. doi: 10.1039/d4ra04730c. eCollection 2024 Aug 29.

Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.罗匹尼罗治疗高催乳素血症：疗效和耐受性的剂量递增研究。

J Clin Endocrinol Metab. 2024 Jan 18;109(2):e667-e674. doi: 10.1210/clinem/dgad545.

Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial.卡麦角林与二甲双胍联合使用与单独使用二甲双胍相比对多囊卵巢疾病合并高催乳素血症患者月经周期规律性的疗效：一项随机临床试验。

J Obstet Gynaecol India. 2017 Oct;67(5):363-369. doi: 10.1007/s13224-017-1022-3. Epub 2017 Jun 24.

本文引用的文献

Endocrine. 2017 Jan;55(1):239-245. doi: 10.1007/s12020-016-1120-5. Epub 2016 Oct 5.

A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.卡麦角林治疗高催乳素血症患者瓣膜性心脏异常患病率的随访研究。

J Clin Endocrinol Metab. 2016 Nov;101(11):4189-4194. doi: 10.1210/jc.2016-2224. Epub 2016 Aug 29.

Carcinoid valve disease.类癌瓣膜病

Curr Treat Options Cardiovasc Med. 2013 Oct;15(5):544-55. doi: 10.1007/s11936-013-0265-2.

Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.卡麦角林长期治疗对催乳素瘤患者心瓣膜疾病的安全性。

Eur J Endocrinol. 2013 Aug 28;169(3):359-66. doi: 10.1530/EJE-13-0231. Print 2013 Sep.

No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.没有证据表明卡麦角林治疗肢端肥大症会对心脏瓣膜造成损害。

J Clin Endocrinol Metab. 2012 Sep;97(9):E1714-9. doi: 10.1210/jc.2012-1833. Epub 2012 Jun 21.

Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.卡麦角林治疗高催乳素血症患者的心脏瓣膜功能的性别影响：一项回顾性研究。

Clin Endocrinol (Oxf). 2010 Jan;72(1):53-8. doi: 10.1111/j.1365-2265.2009.03608.x. Epub 2009 Apr 17.

Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.用于高泌乳素血症和心脏瓣膜功能障碍的多巴胺激动剂疗法：已取得诸多成果，但仍有更多工作要做。

Heart. 2009 Apr;95(7):522-3. doi: 10.1136/hrt.2008.163345. Epub 2009 Jan 27.

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.心脏瓣膜病与卡麦角林用于治疗泌乳素瘤

Clin Endocrinol (Oxf). 2009 Jan;70(1):104-8. doi: 10.1111/j.1365-2265.2008.03458.x.

Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.在一组服用卡麦角林治疗高催乳素血症的患者中瓣膜性心脏病的患病率。

Endocr Pract. 2008 Sep;14(6):672-7. doi: 10.4158/EP.14.6.672.

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.接受卡麦角林长期治疗的泌乳素瘤患者三尖瓣反流患病率增加。

J Clin Endocrinol Metab. 2008 Oct;93(10):3777-84. doi: 10.1210/jc.2007-1403. Epub 2008 Aug 5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验